Skip to main content

Advertisement

SpringerLink
Log in

Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Temozolomide is the most effective chemotherapy for malignant glioma. Hypersensitivity requiring interruption of therapy may significantly impact patient survival. We have successfully employed temozolomide desensitization followed by metronomic dosing of temozolomide. Our purpose was to report patient characteristics and outcomes in patients with glioma (Grade 2–4) and temozolomide hypersensitivity managed by desensitization and metronomic dosing.

Methods

We performed an observational study of 15 patients at Mayo Clinic (Rochester) with a diagnosis of glioma who underwent temozolomide desensitization with subsequent metronomic dosing from May 2012 to January 2017. We calculated overall and progression-free survival using the Kaplan–Meier method, and log-rank analyses to assess for differences in survival by WHO Grade or treatment initiation.

Results

Median age at time of desensitization was 49.3 years (26.8–64.7 years). Median follow-up after desensitization was 35.5 months. One patient (6.7%) was unable to resume temozolomide due to recurrent allergy. The median time from first desensitization to discontinuation of metronomic temozolomide was 4.2 months (0–15.2 months). Median OS and PFS for the whole sample were 181.7 months and 44.9 months. For Grade 4, OS was 100% at 1 year, 40% at 3 years, 20% at 5 years; and PFS was 60% at 1 year, 40% at 3 years, and 20% at 5 years.

Conclusion

Our results suggest that rapid-desensitization followed by metronomic temozolomide should be considered in patients with glioma who experience hypersensitivity. This strategy provides comparable outcomes to therapy with standard protocols, with the majority of patients able to tolerate temozolomide after desensitization with favorable disease control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. FDA (2015) TEMODAR: highlights of prescribing information. https://bit.ly/35uRsHk(fda.gov)

  2. Villano JL, Seery TE, Bressler LR (2009) Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64(4):647–655. https://doi.org/10.1007/s00280-009-1050-5

    Article  CAS  PubMed  Google Scholar 

  3. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23(1):35–61. https://doi.org/10.1016/s0305-7372(97)90019-0

    Article  CAS  PubMed  Google Scholar 

  4. Dixit S, Baker L, Walmsley V, Hingorani M (2012) Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs 23(10):1099–1106. https://doi.org/10.1097/CAD.0b013e328356f5b0

    Article  CAS  PubMed  Google Scholar 

  5. Koschel D, Handzhiev S, Leucht V, Holotiuk O, Fisseler-Eckhoff A, Höffken G (2009) Hypersensitivity pneumonitis associated with the use of temozolomide. Eur Respir J 33(4):931–934

    Article  CAS  PubMed  Google Scholar 

  6. Sarma N (2009) Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. Am J Clin Dermatol 10(4):264–267. https://doi.org/10.2165/00128071-200910040-00007

    Article  PubMed  Google Scholar 

  7. Deluche E, Leobon S, Touraine F, Clavère P (2014) Two cases of cutaneous drug eruption associated with temozolomide therapy for glioblastoma. Curr Oncol (Toronto, Ont) 21(6):e779–781. https://doi.org/10.3747/co.21.2133

    Article  CAS  Google Scholar 

  8. Virmani P, Chung E, Thomas AA, Mellinghoff IK, Marchetti MA (2015) Cutaneous adverse drug reaction associated with oral temozolomide presenting as dermal and subcutaneous plaques and nodules. JAAD Case Rep 1(5):286–288. https://doi.org/10.1016/j.jdcr.2015.06.012

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pothiawala S, Hsu MY, Yang C, Kesari S, Ibrahimi OA (2010) Urticarial hypersensitivity reaction caused by temozolomide. J Drugs Dermatol JDD 9(9):1142–1144

    PubMed  Google Scholar 

  10. Alonso-Llamazares A, Vega-Castro A, Beitia-Mazuecos JM, Mateo-Borrega B, Cardenas-Contreras R (2012) Rapid desensitization with temozolomide in patients with delayed maculopapular rash. J Investig Allergol Clin Immunol 22(6):448–449

    CAS  PubMed  Google Scholar 

  11. Clayton E, Madamba J, Kong XT, Braskett M (2014) Successful desensitization protocol for delayed cutaneous eruption to temozolomide. J Allergy Clin Immunol In Pract 2(5):626–628. https://doi.org/10.1016/j.jaip.2014.03.016

    Article  Google Scholar 

  12. Mhanna H, Jiménez Blanco A, Valdez Tejeda M, Jukic Beteta K, Sánchez González M, Fernandez Rodriguez C, Vives Conesa R (2011) Desensitization to temozolomide. J Allergy Clin Immunol 127(2):197. https://doi.org/10.1016/j.jaci.2010.12.783

    Article  Google Scholar 

  13. Mónica R-G, De las Heras Gozalo M, de la Barrera EHG, Dominguez JS (2011) Successful desensitization with temozolomide. Ann Allergy Asthma Immunol 106(6):541–542. https://doi.org/10.1016/j.anai.2011.02.009

    Article  PubMed  Google Scholar 

  14. Divekar R, Butterfield J, Maddox D (2016) Successful rapid desensitization to temozolomide: a case series. J Allergy Clin Immunol In Pract 4(3):545–546. https://doi.org/10.1016/j.jaip.2015.12.007

    Article  Google Scholar 

  15. Kong D-S, Lee J-I, Kim WS, Son MJ, Lim DH, Kim ST, Park K, Kim JH, Eoh W, Nam D-H (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16(5):1117–1121

    CAS  PubMed  Google Scholar 

  16. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12(3):289–296. https://doi.org/10.1093/neuonc/nop030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15(2):242–250. https://doi.org/10.1093/neuonc/nos295

    Article  CAS  PubMed  Google Scholar 

  18. Wong ET, Timmons J, Callahan A, O'Loughlin L, Giarusso B, Alsop DC (2016) Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. BMC Cancer 16(1):914. https://doi.org/10.1186/s12885-016-2945-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Woo JY, Yang SH, Lee YS, Lee SY, Kim J, Hong YK (2015) Continuous low-dose temozolomide chemotherapy and microvessel density in recurrent glioblastoma. J Korean Neurosurg Soc 58(5):426–431. https://doi.org/10.3340/jkns.2015.58.5.426

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Simsek C, Esin E, Yalcin S (2019) Metronomic chemotherapy: a systematic review of the literature and clinical experience. J Oncol 2019:5483791. https://doi.org/10.1155/2019/5483791

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/s1470-2045(09)70025-7

    Article  CAS  Google Scholar 

  22. Bent MJVD, Erridge S, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Wick W, Clement PM, Baurain J-F, Mason WP, Wheeler H, Weller M, Aldape KD, Wesseling P, Kros JM, Tesileanu M, Golfinopoulos V, Gorlia T, Baumert BG, French P (2019) Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. J Clin Oncol 37(15_suppl):2000–2000. https://doi.org/10.1200/JCO.2019.37.15_suppl.2000

    Article  Google Scholar 

Download references

Acknowledgements

We thank all patients that were included in this study.

Funding

No funding.

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA

    Bryan J. Neth, Michael W. Ruff, Joon H. Uhm & Derek R. Johnson

  2. Department of Radiology, Mayo Clinic, Rochester, MN, USA

    Derek R. Johnson

  3. Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Rohit D. Divekar & Daniel E. Maddox

Authors
  1. Bryan J. Neth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael W. Ruff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joon H. Uhm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Derek R. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rohit D. Divekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniel E. Maddox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bryan J. Neth.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest pertaining to this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neth, B.J., Ruff, M.W., Uhm, J.H. et al. Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. Cancer Chemother Pharmacol 86, 375–382 (2020). https://doi.org/10.1007/s00280-020-04123-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-020-04123-y

Keywords

Search

Navigation